Latest hypoglycemia Stories

PRINCETON, N.J., April 21, 2011 /PRNewswire/ -- Today, Novo Nordisk announced the launch of the NovoTwist® needle in the United States. The NovoTwist® needle, which is now available for use with several Novo Nordisk pre-filled delivery devices, including Levemir® (insulin detemir [rDNA origin] injection) FlexPen®, NovoLog® (insulin aspart [rDNA origin] injection) FlexPen®, Victoza® (liraglutide [rDNA origin] injection) Pen and other Novo Nordisk pens, is the first...

A new study of older diabetes patients has found that well-controlled blood sugar levels were associated with a lower risk of major complications such as heart attacks, amputation and kidney disease, but the very lowest blood sugar levels were associated with a small but significant increased risk of death. The study published in the June 2011 issue of the journal Diabetes Care, followed more than 70,000 type 2 diabetes patients from Kaiser Permanente who were over 60 years of age for four...

DEERFIELD, Ill., April 18, 2011 /PRNewswire/ -- Any clinician knows that there's a massive amount of new diabetes research and clinical information released daily, which makes keeping pace with best practices almost a full-time job. But Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to helping clinicians stay current and achieve the best possible health outcomes, provides its readers with concise, timely, crucial information to improve outcomes and...

Research: Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomized controlled studiesTwo small randomised trials published on bmj.com today suggest that closed loop insulin delivery (also known as an artificial pancreas) may improve overnight blood glucose control and reduce the risk of nocturnal hypoglycaemia (a sudden drop in blood glucose levels during the night) in adults with type 1 diabetes.The number of people with type 1...

Surgeons from Boston Medical Center (BMC) have found that in diabetic patients undergoing coronary artery bypass graft (CABG) surgery, aggressive glycemic control does not result in any significant improvement of clinical outcomes as compared with moderate control. The findings, to be presented at the 131st annual meeting of the American Surgical Association, also found the incidence of hypoglycemic events increased with aggressive glycemic control.Currently, 40 percent of all patients...

University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.Congenital hyperinsulinism (CHI) is a condition where the body's pancreas produces too much insulin "“ rather than too little as in diabetes "“ so understanding the disease has led to breakthroughs in diabetes treatment.This latest study, published in the journal Diabetes today (Wednesday), was...

Researchers from Mount Sinai School of Medicine have discovered a novel function of brain insulin, indicating that impaired brain insulin action may be the cause of the unrestrained lipolysis that initiates and worsens type 2 diabetes in humans. The research is published this month in the journal Cell Metabolism.Led by Christoph Buettner, MD, Assistant Professor of Medicine in the Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai School of Medicine, the research team first...

New approach lowers blood sugar in both type 1 and type 2 diabetes BOSTON, Feb. 13, 2011 /PRNewswire-USNewswire/ -- Diabetes can result from either a deficiency of insulin (type 1 or insulin-dependent diabetes) or decreased sensitivity to insulin (type 2 diabetes). Researchers at Children's Hospital Boston have discovered a mechanism for normalizing blood sugar that doesn't involve insulin and could offer a new therapeutic approach to both kinds of diabetes. Reporting in Nature Medicine...

COPENHAGEN, Denmark, February 2, 2011 /PRNewswire-FirstCall/ -- - Lixisenatide Meets Primary Efficacy Endpoint With Fewer Hypoglycaemias Zealand Pharma A/S (NASDAQ OMX: ZEAL), a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its...

(Ivanhoe Newswire) -- About 1 million people are affected by type 1 diabetes in the United States. According to a new study, type 1 diabetes could be converted to an asymptomatic, non-insulin dependent disorder by eliminating the actions of a specific hormone.Type 1 diabetes is typically first diagnosed in children and teenagers. It is a disease where the body doesn't produce insulin -- a hormone that is needed to convert sugars, starches, and other food into energy.Glucagon is a hormone...